print_label | resize_label

When oral agents in addition to diet and exercise aren’t enough, consider adding BYDUREON—a once-weekly type 2 diabetes treatment option proven to provide powerful and sustained A1C reductions with the additional benefit of weight loss.1,2*

  • In the DURATION-3 study, over 3 years, BYDUREON provided sustained A1C reductions with the additional benefit of weight loss.  Learn more >

View DURATION-3 Study Design

*BYDUREON is not indicated for the management of obesity, and weight change was a secondary endpoint in clinical trials.

Clinical Data

Impact on A1C.

Impact on A1C.

BYDUREON Pen

Designed to be patient-friendly.

Designed to be patient-friendly.

GLP-1 RA Therapy

Multiple glycemic effects in the body.

Multiple effects of GLP-1 in the body.

SteadySTART™ Program

Get on-site training from a Clinical Educator.

Get on-site training from a Clinical Educator.

CALL 1-855-793-6400

X

DURATION-3: 3-year, randomized, open-label study with a core 26-week phase in which the primary endpoint was change in A1C from baseline at 26 weeks, and a prespecified 130-week extension phase in which patients remained in the treatment arms to which they were randomized. The primary efficacy endpoint at 156 weeks (3 years) was change in A1C from baseline. In this study, adult type 2 diabetes patients with suboptimal glycemic control (A1C 7.1%-11%) despite maximum tolerated doses of metformin alone or with a sulfonylurea were assigned to once-weekly BYDUREON 2 mg or once-daily insulin glargine titrated to target using the INITIATE algorithm. Of the 456 randomized patients, 287 completed 3 years of treatment. Patient demographics (modified ITT): BYDUREON: 52% male, 82% Caucasian; mean age, 58 years; A1C, 8.3%; weight, 200.4 lb; fasting plasma glucose (FPG), 178.2 mg/dL; mean duration of diabetes, 8 years. Insulin glargine: 55% male, 85% Caucasian; mean age, 58 years; A1C, 8.3%; weight, 199.3 lb; FPG, 174.6 mg/dL; mean duration of diabetes, 7.8 years.1

CLOSE

When oral agents in addition to diet and exercise aren’t enough, consider adding BYDUREON—a once-weekly type 2 diabetes treatment option proven to provide powerful and sustained A1C reductions with the additional benefit of weight loss.1,2*

  • In the DURATION-3 study, over 3 years, BYDUREON provided sustained A1C reductions with the additional benefit of weight loss.  Learn more >

View DURATION-3 Study Design

*BYDUREON is not indicated for the management of obesity, and weight change was a secondary endpoint in clinical trials.

Versus insulin glargine.

*BYDUREON is not indicated for the management of obesity, and weight change was a secondary endpoint in clinical trials.